These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 17716129)

  • 1. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
    Stinchcombe TE
    Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
    Foote M
    Biotechnol Annu Rev; 2007; 13():345-57. PubMed ID: 17875482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
    Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
    Guarneri V; Dieci MV; Conte P
    Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. nab-Paclitaxel mechanisms of action and delivery.
    Yardley DA
    J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-bound Paclitaxel: in metastatic breast cancer.
    Robinson DM; Keating GM
    Drugs; 2006; 66(7):941-8. PubMed ID: 16740010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
    Rizvi NA; Riely GJ; Azzoli CG; Miller VA; Ng KK; Fiore J; Chia G; Brower M; Heelan R; Hawkins MJ; Kris MG
    J Clin Oncol; 2008 Feb; 26(4):639-43. PubMed ID: 18235124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy evaluation of albumin-bound paclitaxel.
    Cecco S; Aliberti M; Baldo P; Giacomin E; Leone R
    Expert Opin Drug Saf; 2014 Apr; 13(4):511-20. PubMed ID: 24559090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
    J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
    Lipp HP
    Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
    Li Y; Chen N; Palmisano M; Zhou S
    Mol Pharm; 2015 Apr; 12(4):1308-17. PubMed ID: 25714793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
    Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.
    Battogtokh G; Kang JH; Ko YT
    Eur J Pharm Biopharm; 2015 Oct; 96():96-105. PubMed ID: 26212785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.
    Gupta N; Hatoum H; Dy GK
    Int J Nanomedicine; 2014; 9():209-21. PubMed ID: 24399877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
    Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.
    Aapro M; Tjulandin S; Bhar P; Gradishar W
    Breast; 2011 Oct; 20(5):468-74. PubMed ID: 21843943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.